A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder

Trial Profile

A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Vilazodone (Primary) ; Citalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 04 Jun 2015 Results of post hoc analysis have been published in International clinical psychopharmacology.
    • 16 Mar 2015 Based on results of this trial the US FDA approved a supplemental NDA for a lower therapeutic dose of vilazodone (20mg), according to an Actavis media release; the approval fulfils a post-marketing commitment to identify the minimum effective dose.
    • 12 Dec 2014 Results published in the International Clinical Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top